There are 3397 resources available
1192P - Smoking adversely affects survival of metastatic lung carcinoid patients: Analysis of a large international audit
Presenter: Sara Valpione
Session: Poster session 13
1193P - Evaluation of treatment appropriateness in patients submitted to surgery for non-functioning pancreatic neuroendocrine tumors (NF-PanNETs)
Presenter: Anna Battistella
Session: Poster session 13
1194P - Do metastatic appendiceal NETs ever develop metachronously after appendectomy or right hemicolectomy?
Presenter: Taymeyah Al-Toubah
Session: Poster session 13
1195P - Neuroendocrine Tumors (NETs): How Big Data (BD) techniques applied to Electronic Health Records (EHR) can improve our understanding of this patient population
Presenter: Jorge Hernando
Session: Poster session 13
1196P - Regional lymph node metastasis risk factors for rectal neuroendocrine tumors: A population-based study
Presenter: Dan Cao
Session: Poster session 13
1197P - Somatostatin analogs or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors
Presenter: Maria Grazia Maratta
Session: Poster session 13
1198P - Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings
Presenter: Jonathan Strosberg
Session: Poster session 13
1199P - MAVERIC: Phase II randomized study of everolimus as maintenance therapy for metastatic neuroendocrine neoplasms (mNEN) with pulmonary or gastroenteropancreatic (GEP) origin. Results on behalf of the GOIRC
Presenter: Lorenzo Antonuzzo
Session: Poster session 13
1200P - A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial
Presenter: oOttavia Clemente
Session: Poster session 13
1201P - Evaluation of efficacy TEMCAP regiment as first-line or further line therapy in patients with advanced, unresectable, progressive GEP-NET. Real-world data
Presenter: Agnieszka Kolasinska-Cwikla
Session: Poster session 13